FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (139)Camizestrant combination delayed time to first progression in patients with advanced HR-positive breast cancer with an ESR1 tumour mutation
Preheader (150)Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer
Arial
Text Analysis
Body Words169
Subject Words19
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px840 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeAfternoon
